AUTHORS
Xavier Poire, MD, PhD, Maud Ngoya2, Mohamed Youyou3, Raynier Devillier, PhD4, Anna Maria Raiola, MD5, Fabio Ciceri6, Stefania Bramanti, MD7, Lucia Lopez Corral8, Helene Labussiere Wallet9, Mohamad Mohty, MD, PhD10, Alessandro Busca11, Jakob Passweg12, Dominik Schneidawind13, Martin Carre, MD14, Patrice Chevallier15, Maija Itala-Remes16, Giovanni Grillo, MD17, Ibrahim Yakoub-Agha18, Jan Vydra19, Luca Castagna, MD20, Simona Piemontese21, Giorgia Battipaglia22, Annalisa Ruggeri, MD23, Jaime Sanz, MD, PhD24, Eolia Brissot, MD, PhD25
AFFILIATIONS
1 Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium
2 EBMT Office, Paris, France
3 EBMT Office, Paris, France
4 Institut Paoli Calmette, Programme de Transplantation&Therapie Cellulaire, Marseille, France
5 AOM-IRCCS Ospedale Policlinico San Martino, Genova, Italy
6 Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Scientific Institute, Milano, Italy
7 Instituto Clinico Humanitas, Milano, Italy
8 Hospital Clinico, Salamanca, Spain
9 Centre Hospitalier Lyon Sud, Lyon, France
10 Sorbonne University, INSERM UMR S 938, Hôpital Saint-Antoine, Paris, France
11 SSD Trapianto di Cellule Staminali, Torino, Italy
12 University Hospital Basel, Basel, Switzerland
13 University Hospital Zurich, Zurich, Switzerland
14 CHU Grenoble Alpes, Grenoble, France
15 CHU Nantes, Nantes, France
16 Turku University Hospital, Turku, Finland
17 ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
18 17 CHU Lille, Lille, France
19 18 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
20 UOD Trapianti di midollo osseo, Palermo, Italy
21 Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Scientific Institute, Milano, Italy
22 Federico II University of Naples, Hematology Department, Naples, Italy
23 Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Hospital, Scientific Institute, Milano, Italy
24 Hematology Department, Hospital Universitari I Politècnic La Fe, Departament de Medicina Universitat de Valencia, Valencia, Spain
25 Sorbonne University, INSERM UMR S 938, Hôpital Saint-Antoine, Paris, France
ABSTRACT
BACKGROUND: Selection of a suitable donor for allogeneic hematopoetic cell transplantation (allo-HCT) has mainly relied on HLA matching. However, with the widespread use of post-transplant cyclophosphamide (PTCy), haplo-identical donors (HID) and subsequently 9/10 mismatched unrelated donors (MMUD) have been extensively used with impressive results, thus increasing the number of potential donors. In the absence of a matched donor, both HID and MMUD might be considered. As donor’s age is an important factor in donor selection, we retrospectively compared young MMUD to HID in elderly patients with acute myeloid leukemia (AML) transplanted in first remission using PTCy-based graft-versus-host disease (GvHD) prophylaxis. We focused on elderly patients because they often have access to both older sibling and younger offspring HID.
METHODS: From the EBMT registry, we selected patients with AML, aged ≥ 60 years old (yo) and transplanted in first remission between 2015 and 2024, either from HID ≤ 40 yo, HID ≥ 50 yo or MMUD ≤ 40 yo. All patients received PTCy as GvHD prophylaxis.
RESULTS: A total of 1129 patients met the inclusion criteria; 777 HID ≤ 40 yo (69%), 163 HID ≥ 50 yo and 189 MMUD ≤ 40 yo. Median patients age was 65 years (interquartile range IQR 62-68) and median follow-up was 2.6 years (range 2.3-2.9). Time from diagnosis to allo-HCT was longer for MMUD than other donor type (5.9 months, IQR 4.6-7.6 versus 5.3 months, IQR 4.1-6.8, p=0.0009). Bone marrow was the stem cell source more frequently used in HID grafts (p<0.0001). No difference was observed between groups regarding patients’ cytomegalovirus (CMV) status, comorbidities, performance status, cytogenetics risk and conditioning intensity. The main cause of death was disease progression followed by infection and GvHD.
The 2-year probability of GvHD-free and relapse-free survival (GRFS) for the entire cohort was 47%, with no significant differences between HID ≤ 40 yo, HID ≥ 50 yo and MMUD ≤ 40 yo (p=0.59). Accordingly, the 2-year probability of leukemia-free survival (LFS) and overall survival (OS) was 55% and 59.7%, respectively, with no difference between donor type. The 2-year cumulative incidence of relapse (RI) was 20.4% for HID ≤ 40 yo, 16.4% for HID ≥ 50 yo and 24.9% for MMUD ≤ 40 yo (p=0.06). The cumulative incidence of non-relapse mortality (NRM) was 23.8% for HID ≤ 40 yo, 30.4% for HID ≥ 50 yo and 21.8% for MMUD ≤ 40 yo (p=0.08). The cumulative incidence of grade II-IV acute GvHD was 26.2% for HID ≤ 40 yo, 38% for HID ≥ 50 yo and 31.1% for MMUD ≤ 40 yo (p=0.009). The cumulative incidence of grade III-IV acute GvHD was 10.6% and, of chronic GvHD was 28.7%, with no difference between donor groups.
In multivariate analysis, it was confirmed that there was no impact of donor type on GRFS, LFS and OS. However, MMUD ≤ 40 yo were associated with higher risk of RI compared to HID ≤ 40 yo (hazard ratio [HR]= 1.58, 95% confidence interval [CI] 1.03-2.42, p=0.04). NRM was higher with HID ≥ 50 yo compared to HID ≤ 40 yo (HR=1.37, 95%CI 0.95-1.96, p=0.09). The cumulative incidence of grade II-IV acute GvHD was significantly higher with HID ≥ 50 yo (p=0.002) and MMUD ≤ 40 yo (p=0.02) compared to HID ≤ 40 yo. The cumulative incidence of chronic GvHD was lower for MMUD ≤ 40yo (p=0.04). No difference was observed in terms of grade III-IV acute GvHD and extensive chronic GvHD. Additionally, we confirmed the significant impact on the outcomes of both performance status and cytogenetic risk. There was no impact of conditioning intensity or CMV status.
CONCLUSIONS: In patients ≥ 60 yo with AML in first remission with no available matched donor, there was no difference in terms of GRFS, LFS and OS between HID and MMUD. However, because HID ≥ 50 yo were independently associated with higher risk of NRM, and MMUD ≤ 40 yo were associated with higher relapse risk, the best mismatched donor to be considered might be young HID, such as offsprings, but future data is needed to confirm this statement.
DISCLOSURES
Xavier Poire, MD, PhD: No relevant conflicts of interest to declare.